Inhibition of the PI3K/AKT pathway using the inhibitor BKM120, known for its efficacy in various cancers including esophageal carcinoma, breast cancer, glioblastoma, and neuroendocrine cervical carcinoma cell lines, was subsequently explored [30,31]. This evidence concerns the gene AKT1 and breast cancer.